Skip to main content
Premium Trial:

Request an Annual Quote

Rush University Selects BioFortis Software to Manage Methylation Biomarker Data


BioFortis said this week that investigators at Rush University Medical Center will use its Labmatrix database software to manage its biobank and biomarker data for research efforts focused on early detection and diagnosis of cancer and neurodegenerative diseases.

Specifically, the investigators will use Labmatrix to manage patient clinical information, patient biospecimens, operational biobanking workflows, and methylation biomarker research data in a centralized database system.

Furthermore, team members and collaborators can directly retrieve answers to complex questions about collected data from the system using a graphical visual query tool.

In a statement, Victor Levenson, a radiation oncologist at Rush, said the software will enable his team "to centrally track a wide range of scientific data" as well as "easily enter and get all of the relevant upstream and downstream information about disease areas, patients, biosamples, and biomarker profiles."

Last summer, the Catholic Health Initiatives’ Institutes for Research and Innovation’s Center for Translational Research deployed Labmatrix to support specimen biobanking, next-generation diagnostics, biomarker discovery, and translational research (BI 08/27/2010).

The Scan

Test of the China Initiative

According to Science, the upcoming trial of Harvard University chemist Charles Lieber will test the US China Initiative.

Collaborative Approach

A virologist who spotted the Omicron variant of SARS-CoV-2 tells the Associated Press that its detection was aided by scientific sharing.

Genes of a Guide Dog

Wired reports on a study aimed at uncovering genes involved in being a successful guide dog.

PLOS Papers on RNAs in Metastatic Prostate Cancer, Ebola Field Lab, Embryonic RNA Editing

In PLOS this week: circRNA-mediated ceRNA network points to prostate cancer biomarkers, Ebola testing at frontline field laboratory, and more.